One of the first people to take part in a ground-breaking trial for the first lung cancer vaccine in history is a UK patient.
One of the first patients from Europe to take part in a ground-breaking international lung cancer vaccine trial is a patient from the United Kingdom.
With an estimated 1.8 million deaths from the disease in 2020, lung cancer is the most common cause of cancer-related deaths worldwide.
Approximately 230 700 individuals, or nearly a quarter of a million, are from the EU alone, accounting for nearly one in five cancer deaths in the area.
The BNT116 vaccine, created by BioNTech, helps the immune system identify and combat cancer cells by using messenger RNA (mRNA) technology, which is akin to certain COVID-19 vaccinations.
Targeting non-small cell lung cancer (NSCLC), which accounts for 85% of all cases of lung cancer, is the goal of the first-ever injection.
It functions by providing information about common tumor markers linked to non-small cell lung cancer to the patient’s immune system.
Unlike the effects of chemotherapy, this targeted destruction of cancer cells minimizes damage to healthy cells.
“The treatment’s high degree of targeting towards cancer cells is a strength of our current approach. In this way, we hope to demonstrate in due course that the treatment is effective against lung cancer while sparing other tissues,” a statement from the study’s principal investigator, Dr. Sarah Benafif, read.
About 130 patients with different stages of non-small cell lung cancer (NSCLC) from early stages before surgery or radiation therapy to late-stage disease will be included in this innovative study, which will take place across 34 research sites in seven countries.
The experiment is being conducted in the United States, Turkey, Germany, Spain, Poland, and Hungary in addition to the United Kingdom.
Leading the UK study is Professor Siow Ming Lee. “We hope this will provide an opportunity to further improve outcomes for our NSCLC patients, whether in the early or advanced stages,” she stated.
‘Revolutionary’ vaccine providing hope
The 67-year-old London-born scientist Janusz Racz is the first person in the UK to receive the novel experimental vaccination.
Racz started receiving chemotherapy and radiation treatment not long after receiving a lung cancer diagnosis in May.
He expressed optimism that the vaccine would offer protection against cancer cells in a recent statement, saying, “I also thought that my participation in this research could help other people in the future and contribute to making this therapy more widely available.”
Specialising in artificial intelligence (AI), Racz stated that he was motivated to participate in the trial by his scientific background.
As a scientist, I am aware that participation in initiatives such as these is necessary for scientific advancement. I am willing to try new things, and I work in artificial intelligence. My family was supportive of my participation in the trial and had also done research on it,” he said.
Vaccinating people against their own cancers could be “revolutionary” in preventing the disease from recurring, according to Dame Cally Palmer, national cancer director of NHS England.
“A cancer diagnosis is very worrying, but access to groundbreaking trials – alongside other innovations to diagnose and treat cancers earlier – provides hope,” Palmer stated.
“We expect to see thousands more patients taking part in trials over the next few years” .
